Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

ClinicalTrials.gov ID: NCT00036205

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00036205. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.

Study identification

NCT ID
NCT00036205
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
984 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2000 (Type not available)
Primary completion
Not listed
Completion
Dec 2004 (Type not available)
Last update posted
Jan 18, 2007

2000 – 2004

United States locations

U.S. sites
103
U.S. states
38
U.S. cities
103
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama — —
Pfizer Investigational Site Peoria Arizona — —
Pfizer Investigational Site Tucson Arizona — —
Pfizer Investigational Site Little Rock Arkansas — —
Pfizer Investigational Site Concord California — —
Pfizer Investigational Site Fresno California — —
Pfizer Investigational Site Irvine California — —
Pfizer Investigational Site La Jolla California — —
Pfizer Investigational Site Loma Linda California — —
Pfizer Investigational Site Los Angeles California — —
Pfizer Investigational Site Oceanside California — —
Pfizer Investigational Site San Diego California — —
Pfizer Investigational Site San Francisco California — —
Pfizer Investigational Site San Luis Obiapo California — —
Pfizer Investigational Site Sunnyvale California — —
Pfizer Investigational Site Walnut Creek California — —
Pfizer Investigational Site Denver Colorado — —
Pfizer Investigational Site Englewood Colorado — —
Pfizer Investigational Site Fairfield Connecticut — —
Pfizer Investigational Site Hartford Connecticut — —
Pfizer Investigational Site New Haven Connecticut — —
Pfizer Investigational Site Trumbull Connecticut — —
Pfizer Investigational Site Wilmington Delaware — —
Pfizer Investigational Site Boca Raton Florida — —
Pfizer Investigational Site Clearwater Florida — —
Pfizer Investigational Site Fort Lauderdale Florida — —
Pfizer Investigational Site Jacksonville Florida — —
Pfizer Investigational Site Maitland Florida — —
Pfizer Investigational Site Miami Florida — —
Pfizer Investigational Site Naples Florida — —
Pfizer Investigational Site Orlando Florida — —
Pfizer Investigational Site Palm Beach Gardens Florida — —
Pfizer Investigational Site Plantation Florida — —
Pfizer Investigational Site Sarasota Florida — —
Pfizer Investigational Site St. Petersburg Florida — —
Pfizer Investigational Site Tallahassee Florida — —
Pfizer Investigational Site Tampa Florida — —
Pfizer Investigational Site Atlanta Georgia — —
Pfizer Investigational Site Decatur Georgia — —
Pfizer Investigational Site Marietta Georgia — —
Pfizer Investigational Site Savannah Georgia — —
Pfizer Investigational Site Chicago Illinois — —
Pfizer Investigational Site Elkhart Indiana — —
Pfizer Investigational Site Des Moines Iowa — —
Pfizer Investigational Site Dubuque Iowa — —
Pfizer Investigational Site Kansas City Kansas — —
Pfizer Investigational Site Lenexa Kansas — —
Pfizer Investigational Site Crestview Hills Kentucky — —
Pfizer Investigational Site Covington Louisiana — —
Pfizer Investigational Site Lake Charles Louisiana — —
Pfizer Investigational Site Scarborough Maine — —
Pfizer Investigational Site Baltimore Maryland — —
Pfizer Investigational Site Elkridge Maryland — —
Pfizer Investigational Site Frederick Maryland — —
Pfizer Investigational Site Boston Massachusetts — —
Pfizer Investigational Site Bingham Farms Michigan — —
Pfizer Investigational Site Farmington Hills Michigan — —
Pfizer Investigational Site Grand Rapids Michigan — —
Pfizer Investigational Site Royal Oak Michigan — —
Pfizer Investigational Site Traverse City Michigan — —
Pfizer Investigational Site Fridley Minnesota — —
Pfizer Investigational Site Golden Valley Minnesota — —
Pfizer Investigational Site Minneapolis Minnesota — —
Pfizer Investigational Site Saint Cloud Minnesota — —
Pfizer Investigational Site Lee's Summit Missouri — —
Pfizer Investigational Site Salisbury Missouri — —
Pfizer Investigational Site Springfield Missouri — —
Pfizer Investigational Site Omaha Nebraska — —
Pfizer Investigational Site Las Vegas Nevada — —
Pfizer Investigational Site Lebanon New Hampshire — —
Pfizer Investigational Site Morristown New Jersey — —
Pfizer Investigational Site New Brunswick New Jersey — —
Pfizer Investigational Site Manhasset New York — —
Pfizer Investigational Site Mineola New York — —
Pfizer Investigational Site Mount Vernon New York — —
Pfizer Investigational Site New York New York — —
Pfizer Investigational Site Rochester New York — —
Pfizer Investigational Site Syracuse New York — —
Pfizer Investigational Site Asheville North Carolina — —
Pfizer Investigational Site Charlotte North Carolina — —
Pfizer Investigational Site Raleigh North Carolina — —
Pfizer Investigational Site Winston-Salem North Carolina — —
Pfizer Investigational Site Canfield Ohio — —
Pfizer Investigational Site Dayton Ohio — —
Pfizer Investigational Site Oklahoma City Oklahoma — —
Pfizer Investigational Site Eugene Oregon — —
Pfizer Investigational Site Norristown Pennsylvania — —
Pfizer Investigational Site Sellersville Pennsylvania — —
Pfizer Investigational Site Upland Pennsylvania — —
Pfizer Investigational Site Knoxville Tennessee — —
Pfizer Investigational Site Memphis Tennessee — —
Pfizer Investigational Site Austin Texas — —
Pfizer Investigational Site Dallas Texas — —
Pfizer Investigational Site Houston Texas — —
Pfizer Investigational Site San Antonio Texas — —
Pfizer Investigational Site Salt Lake City Utah — —
Pfizer Investigational Site Burlington Vermont — —
Pfizer Investigational Site Charlottesville Virginia — —
Pfizer Investigational Site Richmond Virginia — —
Pfizer Investigational Site Bellevue Washington — —
Pfizer Investigational Site Wenatchee Washington — —
Pfizer Investigational Site Marshfield Wisconsin — —
Pfizer Investigational Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00036205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2007 · Synced Nov 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.